Kenvue stock has struggled this year, but an acquisition offer is giving investors hope leading up to this week's earnings report.

Kenvue stock soars as Kimberly-Clark agrees to acquire the consumer health giant. Jim Cramer is positive on KVUE shares heading into 2026.

Kenvue (NYSE:KVUE), the consumer healthcare spin-off from Johnson & Johnson, has experienced a significant decline in its stock price in recent months.

Kenvue stock share price today shows a major surge after Kimberly-Clark announced plans to buy Kenvue for over $40 billion. The cash-and-stock deal will merge brands like Huggies, Kleenex, Tylenol, and Band-Aid under one company,

The announcement comes just weeks after President Trump publicly spread debunked claims that Tylenol consumption is linked to autism.

Kenvue faces declining sales and high debt post-spin-off. Read why a dividend cut may be imminent and why KVUE stock is a Sell.